Immunity, Inflammation and Disease (Nov 2023)

The DC–T cell axis is an effective target for the treatment of non‐small cell lung cancer

  • Shuangcui Wang,
  • Guan Zhang,
  • Qian Cui,
  • Yanjie Yang,
  • Dong Wang,
  • Aqing Liu,
  • Ying Xia,
  • Wentao Li,
  • Yunhe Liu,
  • Jianchun Yu

DOI
https://doi.org/10.1002/iid3.1099
Journal volume & issue
Vol. 11, no. 11
pp. n/a – n/a

Abstract

Read online

Abstract The dendritic cell (DC)‐T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen‐presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non‐small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.

Keywords